ClinicalTrials.gg
CompletedNCT04660799Updated Oct 12, 2023Results posted

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 interventional study of Rituximab IV and Rituximab SC in Lymphoma, Large B-Cell, Diffuse, sponsored by Hoffmann-La Roche. Completed at 8 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
90th of 211
50 · median 46
Started
2021
with 4 others
Phase 2
119 of 218
12 open now
Registered
185th of 218
by date
Lead sponsor
7 of 218
Hoffmann-La Roche

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 90th largest by enrollment of the 211 interventional ones that give a count, is one of 5 that started in 2021, is one of 119 in phase 2, and was the 185th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a multicenter China-only study to investigate the PK, efficacy and safety of SC rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated participants with CD20 positive DLBCL. Participants will be randomized to receive eight cycles of rituximab SC or rituximab IV combined with six or eight cycles of standard CHOP chemotherapy. After the end of study treatment, participants will be followed-up every 3 months for 6 months.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • Mabthera, Rituximab, SC, Subcutaneous, DLBCL
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL)
  • Participants with an International Prognostic Index (IPI) score of 1 to 5 or IPI score of 0 with bulky disease, defined as one lesion >/=7.5 cm
  • At least one bi-dimensionally defined as >/=1.5 cm in its largest dimension on CT scan
  • (ECOG) performance status of 0, 1, or 2
  • (LVEF) >/=50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram
  • A negative serum pregnancy test or a negative urine pregnancy test within 7 days prior to study treatment
  • For men who are not surgically sterile, agreement to use a barrier method of during the treatment period and until >/=12 months after the last dose of rituximab SC or rituximab IV or according to institutional guidelines for CHOP chemotherapy, whichever is longer, and agreement to request that their partners use an additional method of contraception
  • For women of who are not surgically sterile, agreement to use adequate methods of contraception during the treatment period and until >/=12 months after the last dose of rituximab SC or rituximab IV or according to institutional guidelines for CHOP chemotherapy, whichever is longer
  • Adequate hematologic function confirmed within 14 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Transformed non-Hodgkin's lymphoma (NHL) or types of NHL other than DLBCL and its subtypes according to World Health Organization classification
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to any of the individual components of CHOP, including prior receipt of anthracyclines
  • Prior therapy for DLBCL, with the exception of nodal or local irradiation or surgery for diagnosis
  • Prior treatment with cytotoxic drugs or rituximab for another condition (e.g.,rheumatoid arthritis) or prior use of an anti-CD20 antibody
  • Current or recent treatment with another drug or participation in another investigational therapeutic study
  • Ongoing use (>30 mg/day of prednisone or equivalent)
  • Primary CNS lymphoma, blastic variant of mantle cell lymphoma, or histologic evidence of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, and primary cutaneous DLBCL
  • History of other that could affect compliance with the protocol or interpretation of results
  • Evidence of significant, uncontrolled concomitant diseases including but not limited to significant cardiovascular disease or pulmonary disease
  • Any of the following abnormal laboratory values: creatinine >1.5 (ULN), (AST) / alanine aminotransferase (ALT) >2.5ULN, total >1.5ULN, - international normalized ratio (PT-INR) / partial thromboplastin time (PTT) / activated partial thromboplastin time (aPTT)>1.5ULN
  • Positive test results for chronic (HBV) and or (HCV) infection; Participants with occult or prior HBV infection (defined as negative HBsAg and positive total hepatitis B core antibody [HBcAb]) may be included if HBV DNA is undetectable; Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
  • Known history of (HIV)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Rituximab IV+CHOP

    Participants will receive 8 cycles of IV rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.

    Drug: Rituximab IV · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Paracetamol · Drug: Diphenhydramine hydrochloride or alternative antihistamine

  • Experimental
    Rituximab SC+CHOP

    Participants will receive 1 cycle of IV plus 7 cycles of SC rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.

    Drug: Rituximab SC · Drug: Rituximab IV · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Paracetamol · Drug: Diphenhydramine hydrochloride or alternative antihistamine

Interventions

  • Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).

    Also known as: MabThera

  • Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).

    Also known as: MabThera

  • Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.

    Also known as: MabThera

  • Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2

  • Doxorubicin will be administered IV at a dose of 50 mg/m\^2

  • Vincristine will be administered IV at a dose of 1.4 mg/m\^2

  • Prednisone will be administered orally at a dose of 100 mg/day

  • All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab

  • DrugDiphenhydramine hydrochloride or alternative antihistamine

    All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab

06

What researchers measure

Primary outcomes

  1. Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)

    For this pharmacokinetics (PK) primary outcome measure the serum rituximab Ctrough for SC and IV administrations were measured at Cycle 7, 21 days after study treatment administration for Cycle 7 (pre-dose of Cycle 8). Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis.

    Time frame: At Cycle 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks

Secondary outcomes

  1. Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)

    The area under the curve (AUC) for serum rituximab concentration versus time after dosage was measured for SC and IV administrations during Cycle 7. Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis.

    Time frame: During Cycle 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

  2. Maximum Observed Serum Concentration (Cmax) of Rituximab

    Time frame: At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

  3. Time to Cmax (Tmax) of Rituximab

    Time frame: At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

  4. Trough Serum Concentration (Ctrough) of Rituximab

    Ctrough was measured at Cycle 2 and Cycle 7, 21 days after study treatment administration for each cycle (pre-dose of Cycle 3 and Cycle 8, respectively).

    Time frame: At Cycles 2 and 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks

  5. Area Under the Curve (AUC) of Rituximab

    AUC is the area under the serum concentration curve over the dosing interval of 21 days during Cycle 2 and Cycle 7.

    Time frame: During Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

  6. Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma

    Per LRC, CR based on positron emission tomography- computed tomography (PET-CT) was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake \> mediastinum but ≤ liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, immunohistochemistry (IHC) negative.

    Time frame: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

  7. Objective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma

    ORR=CR+PR. Per LRC: CR by PET-CT: complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions, no FDG-avid disease in bone marrow; CR by CT: complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi, no extralymphatic disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow; PR by PET-CT: partial MR in lymph nodes and extralymphatic sites with a score of 4 or 5 with reduced uptake compared with baseline + residual masses of any size; no new lesions, residual uptake higher than in normal bone marrow but reduced compared with baseline; PR by CT: ≥ 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target nodes and extranodal sites; non-measured lesion absent/normal, regressed, but no increase; spleen regressed by \>50 % in length beyond normal; no new lesions.

    Time frame: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

  8. CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines

    CRR was assessed according to the IWG Response Criteria for NHL 1999 guidelines and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment.

    Time frame: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

  9. CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma

    Per LRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake \> mediastinum but ≤ liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative.

    Time frame: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

  10. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a subject administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. New disease, exacerbation of existing disease, recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test associated with symptoms or leading to a change in study/concomitant treatment or discontinuation from study drug as well as events related to protocol-mandated interventions are considered AEs. SAEs: any event that met any of these criteria: fatal, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, medically significant or required intervention to prevent any of the outcomes listed here.

    Time frame: AEs were reported up to 28 days after the last dose (up to approximately 7 months), and SAEs were reported up to 6 months after the last dose of study treatment (up to approximately 1 year)

  11. Number of Participants With Rituximab Administration-related Reactions (ARRs)

    Adverse events occurring within 24 hours after administration of rituximab (rituximab IV or rituximab SC) and considered related to the study drug, were considered as ARRs. ARRs could present with one or more of the following symptoms: allergic reaction, arthralgia, bronchospasm, chills, cough, dizziness, dyspnoea, headache, hypertension, hypotension, myalgia, nausea, pruritus, pyrexia, rash, tachycardia, urticaria, vomiting.

    Time frame: Up to 24 hours after the last dose of study treatment (up to approximately 24 weeks)

  12. Number of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab

    Reported here is the number of participants who had a positive ADA assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced ADAs and treatment-induced ADAs. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced ADAs include participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

    Time frame: From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)

  13. Number of Participants Positive for Anti-rHuPH20 Antibodies

    Reported here is the number of participants who had a positive anti-rHuPH20 antibody assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced anti-rHuPH20 antibodies and treatment-induced anti-rHuPH20 antibodies. Treatment-enhanced anti-rHuPH20 antibodies are participants with a positive anti-rHuPH20 antibody result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced anti-rHuPH20 antibodies include participants with negative or missing baseline anti-rHuPH20 antibody result(s) and at least one positive post-baseline anti-rHuPH20 antibody result.

    Time frame: From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)

07

Results

Posted Jul 27, 2023

Participant flow

This study was conducted at 9 centers in China.

Participant flow — Overall Study
MilestoneRituximab IV+CHOPRituximab SC+CHOP
Started2426
Completed1718
Not completed78
Withdrew: Progressive disease11
Withdrew: Death21
Withdrew: Adverse event21
Withdrew: Withdrawal by subject25

Outcome measures

PrimarySubcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)

For this pharmacokinetics (PK) primary outcome measure the serum rituximab Ctrough for SC and IV administrations were measured at Cycle 7, 21 days after study treatment administration for Cycle 7 (pre-dose of Cycle 8). Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis.

Time frame:
At Cycle 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks
Reported as:
Geometric mean · micrograms/milliliter (mcg/mL)
Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)
micrograms/milliliter (mcg/mL)Rituximab IV+CHOPRituximab SC+CHOP
Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)90.7 ± 21.1137.4 ± 36.3
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Ratio ctrough sc/ctrough iv: 1.52 · 90% CI 1.28 to 1.79
SecondaryObserved SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)

The area under the curve (AUC) for serum rituximab concentration versus time after dosage was measured for SC and IV administrations during Cycle 7. Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis.

Time frame:
During Cycle 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks
Reported as:
Geometric mean · day*mcg/mL
Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)
day*mcg/mLRituximab IV+CHOPRituximab SC+CHOP
Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)3050.7 ± 17.83806.7 ± 27.2
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Geometric mean ratio of aucsc/auciv: 1.25 · 90% CI 1.10 to 1.42
SecondaryMaximum Observed Serum Concentration (Cmax) of Rituximab
Time frame:
At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of Rituximab
micrograms per milliliter (mcg/mL)Rituximab IV+CHOPRituximab SC+CHOP
Cycle 2200 ± 18.3144 ± 29.6
Cycle 7255 ± 14.6228 ± 28.3
SecondaryTime to Cmax (Tmax) of Rituximab
Time frame:
At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks
Reported as:
Median · day
Time to Cmax (Tmax) of Rituximab
dayRituximab IV+CHOPRituximab SC+CHOP
Cycle 20.14 (0.09 to 0.94)5.42 (1.88 to 13.90)
Cycle 70.16 (0.10 to 1.03)1.99 (1.84 to 6.91)
SecondaryTrough Serum Concentration (Ctrough) of Rituximab

Ctrough was measured at Cycle 2 and Cycle 7, 21 days after study treatment administration for each cycle (pre-dose of Cycle 3 and Cycle 8, respectively).

Time frame:
At Cycles 2 and 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks
Reported as:
Geometric mean · mcg/mL
Trough Serum Concentration (Ctrough) of Rituximab
mcg/mLRituximab IV+CHOPRituximab SC+CHOP
Cycle 243.2 ± 26.563.5 ± 36.9
Cycle 790.7 ± 21.1137 ± 36.3
SecondaryArea Under the Curve (AUC) of Rituximab

AUC is the area under the serum concentration curve over the dosing interval of 21 days during Cycle 2 and Cycle 7.

Time frame:
During Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks
Reported as:
Geometric mean · day*mcg/mL
Area Under the Curve (AUC) of Rituximab
day*mcg/mLRituximab IV+CHOPRituximab SC+CHOP
Cycle 21730 ± 21.52130 ± 31.1
Cycle 73050 ± 17.83810 ± 27.2
SecondaryComplete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma

Per LRC, CR based on positron emission tomography- computed tomography (PET-CT) was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake \> mediastinum but ≤ liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, immunohistochemistry (IHC) negative.

Time frame:
6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)
Reported as:
Number · percentage of participants
Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma
percentage of participantsRituximab IV+CHOPRituximab SC+CHOP
Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma62.5 (40.59 to 81.20)80.8 (60.65 to 93.45)
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Difference in crr: 18.27 · 95% CI -8.92 to 45.45
SecondaryObjective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma

ORR=CR+PR. Per LRC: CR by PET-CT: complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions, no FDG-avid disease in bone marrow; CR by CT: complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi, no extralymphatic disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow; PR by PET-CT: partial MR in lymph nodes and extralymphatic sites with a score of 4 or 5 with reduced uptake compared with baseline + residual masses of any size; no new lesions, residual uptake higher than in normal bone marrow but reduced compared with baseline; PR by CT: ≥ 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target nodes and extranodal sites; non-measured lesion absent/normal, regressed, but no increase; spleen regressed by \>50 % in length beyond normal; no new lesions.

Time frame:
6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma
percentage of participantsRituximab IV+CHOPRituximab SC+CHOP
Investigator70.8 (48.91 to 87.38)88.5 (69.85 to 97.55)
IRC66.7 (44.68 to 84.37)80.8 (60.65 to 93.45)
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Difference in orr investigator: 17.63 · 95% CI -6.86 to 42.11
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Difference in orr irc: 14.10 · 95% CI -12.68 to 40.88
SecondaryCRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines

CRR was assessed according to the IWG Response Criteria for NHL 1999 guidelines and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment.

Time frame:
6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)
Reported as:
Number · percentage of participants
CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines
percentage of participantsRituximab IV+CHOPRituximab SC+CHOP
CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines58.3 (36.64 to 77.89)65.4 (44.33 to 82.79)
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Difference in crr: 7.05 · 95% CI -22.49 to 36.59
SecondaryCRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma

Per LRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake \> mediastinum but ≤ liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative.

Time frame:
6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)
Reported as:
Number · percentage of participants
CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma
percentage of participantsRituximab IV+CHOPRituximab SC+CHOP
CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma58.3 (36.64 to 77.89)76.9 (56.35 to 91.03)
Statistical analysis
  • Rituximab IV+CHOP vs Rituximab SC+CHOP · Difference in crr: 18.59 · 95% CI -9.55 to 46.73
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a subject administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. New disease, exacerbation of existing disease, recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test associated with symptoms or leading to a change in study/concomitant treatment or discontinuation from study drug as well as events related to protocol-mandated interventions are considered AEs. SAEs: any event that met any of these criteria: fatal, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, medically significant or required intervention to prevent any of the outcomes listed here.

Time frame:
AEs were reported up to 28 days after the last dose (up to approximately 7 months), and SAEs were reported up to 6 months after the last dose of study treatment (up to approximately 1 year)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsRituximab IV+CHOPRituximab SC+CHOP
AEs2426
SAEs118
SecondaryNumber of Participants With Rituximab Administration-related Reactions (ARRs)

Adverse events occurring within 24 hours after administration of rituximab (rituximab IV or rituximab SC) and considered related to the study drug, were considered as ARRs. ARRs could present with one or more of the following symptoms: allergic reaction, arthralgia, bronchospasm, chills, cough, dizziness, dyspnoea, headache, hypertension, hypotension, myalgia, nausea, pruritus, pyrexia, rash, tachycardia, urticaria, vomiting.

Time frame:
Up to 24 hours after the last dose of study treatment (up to approximately 24 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Rituximab Administration-related Reactions (ARRs)
ParticipantsRituximab IV+CHOPRituximab SC+CHOP
Number of Participants With Rituximab Administration-related Reactions (ARRs)67
SecondaryNumber of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab

Reported here is the number of participants who had a positive ADA assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced ADAs and treatment-induced ADAs. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced ADAs include participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

Time frame:
From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab
ParticipantsRituximab IV+CHOPRituximab SC+CHOP
Baseline21
Post-baseline: Treatment-enhanced10
Post-baseline: Treatment-induced11
SecondaryNumber of Participants Positive for Anti-rHuPH20 Antibodies

Reported here is the number of participants who had a positive anti-rHuPH20 antibody assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced anti-rHuPH20 antibodies and treatment-induced anti-rHuPH20 antibodies. Treatment-enhanced anti-rHuPH20 antibodies are participants with a positive anti-rHuPH20 antibody result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced anti-rHuPH20 antibodies include participants with negative or missing baseline anti-rHuPH20 antibody result(s) and at least one positive post-baseline anti-rHuPH20 antibody result.

Time frame:
From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-rHuPH20 Antibodies
ParticipantsRituximab SC+CHOP
Baseline2
Post-baseline: Treatment-enhanced1
Post-baseline: Treatment-induced1

Adverse events

Collected over Non-serious adverse events (NSAEs) were reported up to 28 days after the last dose (up to approximately 7 months). Serious adverse events (SAEs) and adverse events of special interest (AESIs) were reported up to 6 months after the last dose of study treatment (up to approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab IV+CHOP2/24 (8.3%)11/24 (45.8%)24/24 (100%)
Rituximab SC+CHOP1/26 (3.8%)8/26 (30.8%)26/26 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventRituximab IV+CHOPRituximab SC+CHOP
Febrile neutropeniaBlood and lymphatic system disorders4/242/26
PneumoniaInfections and infestations2/243/26
Neutrophil count decreasedInvestigations2/241/26
Platelet count decreasedInvestigations2/240/26
White blood cell count decreasedInvestigations2/240/26
MyelosuppressionBlood and lymphatic system disorders1/241/26
Cardiac arrestCardiac disorders1/240/26
Multiple organ dysfunction syndromeGeneral disorders1/240/26
Pneumocystis jirovecii pneumoniaInfections and infestations1/241/26
SepsisInfections and infestations1/240/26
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRituximab IV+CHOPRituximab SC+CHOP
AnaemiaBlood and lymphatic system disorders17/2425/26
White blood cell count decreasedInvestigations20/2421/26
Neutrophil count decreasedInvestigations17/2418/26
Lymphocyte count decreasedInvestigations11/2416/26
Platelet count decreasedInvestigations14/2416/26
AlopeciaSkin and subcutaneous tissue disorders9/2410/26
HyperglycaemiaMetabolism and nutrition disorders8/240/26
Alanine aminotransferase increasedInvestigations4/248/26
Neutrophil count increasedInvestigations4/248/26
HypoaesthesiaNervous system disorders4/248/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rituximab IV+CHOPRituximab SC+CHOPTotal
Mean62.7 ± 10.155.0 ± 15.558.7 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab IV+CHOPRituximab SC+CHOPTotal
Female11920
Male131730
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rituximab IV+CHOPRituximab SC+CHOPTotal
Hispanic or Latino000
Not Hispanic or Latino242650
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rituximab IV+CHOPRituximab SC+CHOPTotal
American Indian or Alaska Native000
Asian242650
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Peking University Third Hospital
    Beijing, 100191, China
  • The First Hospital of Jilin University
    Changchun City, 130021, China
  • Fujian Provincial Cancer Hospital
    Fuzhou City, 350014, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • The 1st Affiliated Hospital of Nanchang Unversity
    Nanchang, 330019, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjing, 300060, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan City, 430023, China
  • The First Affiliated Hospital of Xian Jiao Tong University
    Xi'an City, 710061, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2022, 14 months.

Results were first posted in Jul 2023, 1 year 2 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 14 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 9, 2020
StartActual
Feb 24, 2021
Primary completionActual
May 23, 2022
CompletionActual
Oct 11, 2022
Results first posted
Jul 27, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04660799
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Feb 24, 2021
Primary completion
May 23, 2022
Completion
Oct 11, 2022
Results posted
Jul 27, 2023
Last update
Oct 12, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion